Menarini takes over Furiex's PE drug as Janssen fails to perform
This article was originally published in Scrip
Executive Summary
Janssen Pharmaceutica and ALZA (J&J companies) have returned the rights to the premature ejaculation treatment Priligy (dapoxetine) to Furiex Pharmaceuticals. In turn, Furiex has licensed to Menarini rights to commercialise Priligy in Europe, most of Asia, Africa, Latin America and the Middle East. Furiex will retain development and commercialisation rights in the US, Japan and Canada.